Business Context and Reporting Period
Company: Synthetic Blood International, Inc. (Note: Metadata listed "Tenax Therapeutics," but the filing text identifies the registrant as Synthetic Blood International, Inc.)
Period: Quarterly report (Form 10-Q) for the period ended October 31, 2001.
Status: Development stage company engaged in pre-clinical research for synthetic blood products. The company has no revenue and relies on financing to fund operations.
Key Financial Metrics
| Metric | Six Months Ended Oct 31, 2001 | Six Months Ended Oct 31, 2000 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(1,039,148) | $(762,133) |
| Net Loss Per Share (Basic/Diluted) | $(0.012) | $(0.009) |
| Cash and Cash Equivalents (Oct 31, 2001) | $3,496,526 | $5,099,191 (Oct 31, 2000) |
| Working Capital | $3,234,976 | N/A |
| Total Current Liabilities | $349,341 | N/A |
| Accumulated Deficit | $(14,024,728) | N/A |
Cash Flow Summary (Six Months Ended Oct 31, 2001):
- Net cash used in operating activities: $(897,452)
- Net cash used in investing activities: $(215,239)
- Net cash provided by financing activities: $358,319
Material Changes vs. Prior Period
Expenses:
- Research and Development (R&D): Increased to $667,325 for the six months ended Oct 31, 2001, from $285,038 in the prior year. This 134% increase is attributed to higher wages, contract salaries ($345,000 increase), lab supplies, and equipment depreciation.
- General and Administrative (G&A): Decreased to $452,280 from $658,293 in the prior year. The reduction is due to the absence of one-time professional service expenditures in 2000, specifically decreases in consulting, marketing research, and investor relations costs.
- The net loss increased by $277,015 to $1,039,148. While operating expenses rose, the primary driver for the increased loss was a $95,744 decrease in "Other Income," caused by falling interest rates and smaller invested cash balances.
- The company raised capital through the sale of common stock and exercise of options/warrants, generating $358,319 in net financing cash flow for the six-month period.
Outlook, Risks, and Management Commentary
Liquidity and Capital Resources:
- Management believes current cash ($3.5 million) is sufficient to meet liquidity needs for the next 12 months.
- The company is in the pre-clinical stage and requires significant additional financing for further development, testing, and potential FDA clinical trials.
- There are no firm commitments for additional capital as of October 31, 2001.
- Entered into agreements with Abacus Ventures, LLC and Stephen R. Lairmore to assist in securing financing. These agreements include retainers and success fees payable in cash or stock.
- Regulatory Risk: No assurance that pre-clinical studies will merit FDA approval for clinical trials, or that clinical trials will succeed.
- Financing Risk: Failure to raise adequate financing could force the company to delay, scale back, or eliminate product development programs.
- Dilution: Future equity financing will likely result in dilution of existing shareholders.
- Market Risk: No exposure to foreign currency or interest rate risk via derivatives, though interest income is sensitive to market rates.
Investor Verification Checklist
- Capital Runway: Verify if the $3.5 million cash balance is sufficient to reach the next major milestone (FDA approval for clinical trials) given the burn rate of ~$900k per six months.
- Financing Commitments: Confirm the status of the financing agreements with Abacus Ventures and Stephen R. Lairmore and whether any funding has been secured since the filing date.
- Regulatory Progress: Review the status of pre-clinical studies to assess the likelihood of obtaining FDA approval for clinical trials.
- Dilution Impact: Analyze the impact of the 5.5 million options and warrants issued in September 2001 on future share count and ownership percentage.
- Revenue Timeline: Note that the company has zero revenue; verify management's timeline for potential commercialization or strategic partnerships.